Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025BiomedicinesOpen Access

Determinants of Clinical Remission in Dupilumab-Treated Severe Eosinophilic Asthma: A Real-World Retrospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMatteo BonatoEFElisabetta FaveroFSFrancesca Savoia

Discussion

Loading...

Member takes

Overview

Observational study evaluates remission rates and predictors in patients with severe eosinophilic asthma, highlighting the role of eosinophils and comorbidities.

Key Points

  • Almost half of the patients achieved clinical remission after 12 months of dupilumab treatment, emphasizing the drug's effectiveness.
  • High baseline FEV1 and eosinophil levels significantly predicted better clinical outcomes, showing a strong relationship with remission rates.
  • The study design involved a retrospective observational analysis across two centers, assessing clinical, functional, and biomarker data.
  • Identifying comorbidities such as obesity and bronchiectasis is crucial, highlighting the need for personalized treatment approaches in asthma management.

Cite This Study

Bonato et al. (2025) studied this question.

synapsesocial.com/papers/68dd91dafe798ba2fc4994bfhttps://doi.org/10.3390/biomedicines13102404
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biomarker-Associated Remission with Anti-IL-4R/IL-13 Therapy After Failure of Prior Biologics in Severe Asthma2025
  2. 2Biomarker-Associated Remission After Switching to Dupilumab in Severe Asthma Following Failure of Prior Biologics2025 · 2 citations
  3. 3Comorbidities as a Personalized Target in Patients with Severe Asthma Treated with Dupilumab2025 · 1 citations
  4. 4Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis2026
  5. 5Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness2025 · 17 citations